临床肝胆病杂志

参考文献

[1]BJRNSSON ES,BERGMANN OM,BJRNSSON HK,et al.Incidence,presentation,and outcomes in patients with drug-induced liver injury in the general population of Iceland[J].Gastroenterology,2013,144(7):1419-1425.

[2]FONTANA RJ,WATKINS PB,BONKOVSKY HL,et al.Drug-Induced Liver Injury Network(DILIN)prospective study:rationale,design and conduct[J].Drug Saf,2009,32(1):55-68.

[3]CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol,2014,109(7):950-966.

[4]DEVARBHAVI H.An update on drug-induced liver injury[J].J Clin Exp Hepatol,2012,2(3):247-259.

[5]MIGUEL A,AZEVEDO LF,ARAU'JO M,et al.Frequency of adverse drug reactions in hospitalized patients:a systematic review and meta-analysis[J].Pharmacoepidemiol Drug Saf,2012,21(11):1139-1154.

[6]LI L,JIANG W,WANG JY.Clinical analysis of 275 cases of acute drug-induced liver disease[J].Front Med China,2007,1(1):58-61.

[7]HOOFNAGLE JH,SERRANO J,KNOBEN JE,et al.Liver Tox:a website on drug-induced liver injury[J].Hepatology,2013,57(3):873-874.

[8]MAO YM.Hepa Tox:A professional network platform to promote clinical and translational research of drug-induced liver injury in China[J].Chin Hepatol,2014,19(8):575-576.(in Chinese)茅益民.Hepa Tox:促进中国药物性肝损伤临床和转化研究的专业网络平台[J].肝脏,2014,19(8):575-576.

[9]LARREY D.Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J].Semin Liver Dis,2002,22(2):145-155.

[10]BJORNSSON ES.Epidemiology and risk factors for idiosyncratic drug-induced liver injury[J].Semin Liver Dis,2014,34(2):115-122.

[11]LAI RT,WANG H,GUI HL,et al.Clinical and pathological features in 138 cases of drug-induced liver injury[J].Chin J Hepatol,2012,20(3):185-189.(in Chinese)赖荣陶,王晖,桂红莲,等.138例药物性肝损伤患者的临床特征及肝脏组织学改变[J].中华肝脏病杂志,2012,20(3):185-189.

[12]HAO KY,YU YC,HE CL,et al.RUCAM scale-based diagnosis,clinical features and prognosis of 140 cases of drug-induced liver injury[J].Chin J Hepatol,2014,22(12):82-85.(in Chinese)郝坤艳,于乐成,何长伦,等.基于Roussel uclaf因果关系评估量表的药物性肝损伤140例诊治分析[J].中华肝脏病杂志,2014,22(12):82-85.

[13]RUSSO MW,GALANKO JA,SHRESTHA R,et al.Liver transplantation for acute liver failure from drug induced liver injury in the United States[J].Liver Transpl,2004,10(8):1018-1023.

[14]BJORNSSON E,JERLSTAD P,BERGQVIST A,et al.Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden[J].Scand J Gastroenterol,2005,40(9):1095-1101.

[15]HOU FQ,ZENG Z,WANG GQ.Hospital admissions for drug-induced liver injury:clinical features,therapy,and outcomes[J].Cell Biochem Biophys,2012,64(2):77-83.

[16]STINE JG,LEWIS JH.Drug-induced liver injury:a summary of recent advances[J].Expert Opin Drug Metab Toxicol,2011,7(7):875-890.

[17]HOOFNAGLE JH,NAVARRO VJ.Drug-induced liver injury:Icelandic lessons[J].Gastroenterology,2013,144(7):1335-1336.

[18]LUCENA MI,ANDRADE RJ,KAPLOWITZ N,et al.Phenotypic characterization of idiosyncratic drug-induced liver injury:the influence of age and sex[J].Hepatology,2009,49(6):2001-2009.

[19]ELINAV E,PINSKER G,SAFADI R,et al.Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity[J].J Hepatol,2007,47(4):514-520.

[20]AZIZI F,AMOUZEGAR A.Management of hyperthyroidism during pregnancy and lactation[J].Eur J Endocrinol,2011,164(6):871-876.

[21]MARTINEZ MA,VUPPALANCHI R,FONTANA RJ,et al.Clinical and histologic features of azithromycin-induced liver injury[J].Clin Gastroenterol Hepatol,2015,13(2):369-376.

[22]SAADI T,WATERMAN M,YASSIN H,et al.Metformin-induced mixed hepatocellular and cholestatic hepatic injury:case report and literature review[J].Int J Gen Med,2013,6:703-706.

[23]SORIANO V,PUOTI M,GARCIA-GASCO P,et al.Antiretroviral drugs and liver injury[J].AIDS,2008,22(1):1-13.

[24]ANDRADE RJ,LUCENA MI,KAPLOWITZ N,et al.Outcome of acute idiosyncratic drug-induced liver injury:long-term follow-up in a hepatotoxicity registry[J].Hepatology,2006,44(6):1581-1588.

[25]PAIS R,RUSU E,RATZIU V.The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease[J].Clin Liver Dis,2014,18(1):165-178.

[26]SHARMA SK,BALAMURUGAN A,SAHA PK,et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J].Am J Respir Crit Care Med,2002,166(7):916-919.

[27]PUKENYTE E,LESCURE FX,REY D,et al.Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment[J].Int J Tuberc Lung Dis,2007,11(1):78-84.

[28]MITCHELL JR,LONG MW,THORGEIRSSON UP,et al.Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy[J].Chest,1975,68(2):181-190.

[29]SHAYIQ RM,ROBERTS DW,ROTHSTEIN K,et al.Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice:an explanation for high acetaminophen dosage in humans without hepatic injury[J].Hepatology,1999,29(2):451-63.

[30]WATKINS PB,ZIMMERMAN HJ,KNAPP MJ,et al.Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease[J].JAMA,1994,271(13):992-998.

[31]ZAMOR PJ,RUSSO MW.Liver function tests and statins[J].Curr Opin Cardiol,2011,26(4):338-341.

[32]PADDA MS,SANCHEZ M,AKHTAR AJ,et al.Drug-induced cholestasis[J].Hepatology,2011,53(4):1377-1387.

[33]KHANDELWAL N,JAMES LP,SANDERS C,et al.Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure[J].Hepatology,2011,53(2):567-576.

[34]GUENGERICH FP.Cytochrome P450 activation of toxins and hepatotoxicity[M]//KAPLOWITZ N,DELEVE LD.Drug induced liver disease.3rd ed.Nederland:Elsevier,2013:15-33.

[35]DALY AK,DAY CP.Genetic association studies in drug-induced liver injury[J].Drug Metab Rev,2012,44(1):116-126.

[36]RUSSMANN S,JETTER A,KULLAK-UBLICK GA.Pharmacogenetics of drug-induced liver injury[J].Hepatology,2010,52(2):748-761.

[37]WEI CY,LEE MTM,CHEN YT.Pharmacogenomics of adverse drug reactions:implementing personalized medicine[J].Hum Mol Genet,2012,21(R1):r58-r65.

[38]ALFIREVIC A,GONZALEZ-GALARZA F,BELL C,et al.In silico analysis of HLA associations with drug-induced liver injury use of a HLA-genotyped DNA archive from healthy volunteers[J].Genome Med,2012,4(6):51.

[39]KINDMARK A,JAWAID A,HARBRON CG,et al.Genomewide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis[J].Pharmacogenomics J,2008,8(3):186-195.

[40]SINGER JB,LEWITZKY S,LEROY E,et al.A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury[J].Nature,2010,42(8):711-714.

[41]PESSAYRE D,FROMENTY B,BERSON A,et al.Central role of mitochondria in drug-induced liver injury[J].Drug Metab Rev,2012,44(1):34-87.

[42]GONCALVES RL,ROTHSCHILD DE,QUINLAN CL,et al.Sources of superoxide/H2O2 during mitochondrial proline oxidation[J].Redox Biol,2014,2:901-909.

[43]FAN JG,ZENG MD,LI JQ,et al.Correlation between hepatic fat,lipid peroxidation and hepatic fibrosis in rats chronically fed with ethanol and/or high fat diet[J].Chin J Intern Med,1997,36(12):808-811.(in Chinese)范建高,曾民德,李继强,等.肝内脂肪和脂质过氧化与肝纤维化关系的实验研究[J].中华内科杂志,1997,36(12):808-811.

[44]FINKEL T.Signal transduction by reactive oxygen species[J].J Cell Biol,2011,194:7-15.

[45]CHOUMAR A,TARHUNI A,LETTE'RON P,et al.Lipopolysaccharide-induced mitochondrial DNA depletion[J].Antioxid Redox Signal,2011,15:2837-2854.

[46]KIM JS,HE L,QIAN T,et al.Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes[J].Curr Mol Med,2003,3(6):527-535.

[47]NAKAGAWA H,MAEDA S,HIKIBA Y,et al.Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation[J].Gastroenterology,2008,135(4):1311-1321.

[48]JAESCHKE H,MCGILL MR,WILLIAMS CD,et al.Current issues with acetaminophen hepatotoxicity—a clinically relevant model to test the efficacy of natural products[J].Life Sci,2011,88(17-18):737-745.

[49]MARTIN-MURPHY BV,HOLT MP,JU C.The role of damage associated molecular pattern molecules in acetaminophen induced liver injury in mice[J].Toxicol Lett,2010,192(3):387-394.

[50]JANSSENS S,PULENDRAN B,LAMBRECHT BN.Emerging functions of the unfolded protein response in immunity[J].Nat Immunol,2014,15(10):910-919.

[51]LILY DARA,CHENG JI,NEIL KAPLOWITZ.The contribution of endoplasmic reticulum stress to liver diseases[J].Hepatology,2011,55(5):1752-1763.

[52]FREDRIKSSON L,WINK S,HERPERS B,et al.Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity[J].Toxicol Sci,2014,140(1):144-159.

[53]LAI R,XIANG X,MO R,et al.Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury[J].J Hepatol,2015,63(1):148-155.

[54]MASSON MJ,COLLINS LA,POHL LR.The role of cytokines in the mechanism of adverse drug reactions[J].Handb Exp Pharmacol,2010,196:195-231.

[55]UETRECHT J.Immunoallergic drug-induced liver injury in humans[J].Semin Liver Dis,2009,29(4):383-392.

[56]VANDENABEELE P,GALLUZZI L,VANDEN BERGHE T,et al.Molecular mechanisms of necroptosis:an ordered cellular explosion[J].Nat Rev Mol Cell Biol,2010,11(10):700-714.

[57]KE PY,CHEN SS.Hepatitis C virus and cellular stress response:implications to molecular pathogenesis of liver diseases[J].Viruses,2012,4(10):2251-2290.

[58]HENKEL A,GREEN RM.The unfolded protein response in fatty liver disease[J].Semin Liver Dis,2013,33(4):321-329.

[59]FONTANA RJ.Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J].Gastroenterology,2014,146(4):914-928.

[60]HUSSAINI SH,FARRINGTON EA.Idiosyncratic drug-induced liver injury:an update on the 2007 overview[J].Expert Opin Drug Saf,2014,13(1):67-81.

[61]JU C,REILLY T.Role of immune reactions in drug-induced liver injury(DILI)[J].Drug Metab Rev,2012,44(1):107-115.

[62]CZAJA AJ.Drug-induced autoimmune-like hepatitis[J].Dig Dis Sci,2011,56(4):958-976.

[63]CHALASANI N,BJRNSSON E.Risk factors for idiosyncratic drug-induced liver injury[J].Gastroenterology,2010,138(7):2246-2259.

[64]EISENBERG-LERNER A,KIMCHI A.PKD is a kinase of Vsp34that mediates ROS-induced autophagy downstream of DAPk[J].Cell Death Differ,2012,19(5):788-797.

[65]DING WX,MANLEY S,NI HM.The emerging role of autophagy in alcoholic liver disease[J].Exp Biol Med,2011,236(5):546-556.

[66]ROTH RA,GANEY PE.Role of Inflammation in Drug-Induced Liver Injury[M]//KAPLOWITZ N,DELEVE LD.Drug-induced liver disease.3rd ed.San Diego:Academic Press,2013:157-173.

[67]WU MH,ZANG P,HUANG X.Toll-like receptors in innate immunity and infectious diseases[J].Front Med in China,2010,4(4):385-93.

[68]HANSEN JD,VOJTECH LN,LAING KJ.Sensing disease and danger:a survey of vertebrate PRRs and their origins[J].Dev Comp Immunol,2011,35(9):886-897.

[69]KAPLOWITZ N.Idiosyncratic drug hepatotoxicity[J].Nat Rev Drug Discov,2005,4(6):489-499.

[70]MEHENDALE HM.Tissue repair:an important determinant of final outcome of toxicant-induced injury[J].Toxicol Pathol,2005,33(1):41-51.

[71]KLEINER DE.Histopathological evaluation of drug-inducend liver disease[M]//KAPLOWTTZ N,DELEVE LD,ed.Drug-Induced Liver Disease.3rd Ed.San Diego:Academic Press,2013:241-261.

[72]GOODMAN ZD.Drug hepatotosicity[J].Clin Liver Dis,2002,6(2):381-397.

[73]RAMACHANDRAN R,KAKAR S.Histological patterns in drug-induced liver disease[J].J Clin Pathol,2009,62(6):481-492.

[74]KLEINER DE.The pathology of drug-induced liver injury[J].Semin Liver Dis,2009,29(4):364-372.

[75]LABBE G,PESSAYRE D,FROMENTY B.Drug-induced liver injury through mitochondrial dysfunction:mechanisms and detection during preclinical safety studies[J].Fundam Clin Pharmacol,2008,22(4):335-353.

[76]TANG W.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity[J].Expert Opin Drug Metab Toxicol,2007,3(3):407-420.

[77]HAYASHI PH,FONTANA RJ.Clinical features,diagnosis,and natural history of drug-induced liver injury[J].Semin Liver Dis,2014,34(2):134-144.

[78]ANDRADE RJ,LUCENA MI,FERNANDEZ MC,et al.Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J].Gastroenterology,2005,129(2):512-521.

[79]FONTANA RJ,SEEFF LB,ANDRADE RJ,et al.Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop[J].Hepatology,2010,52(2):730-742.

[80]FONTANA RJ,HAYASHI PH,GU J,et al.Idiosyncratic druginduced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J].Gastroenterology,2014,147(1):96-108.

[81]CHALASANI N,FONTANA RJ,BONKOVSKY HL,et al.Causes,clinical features,and outcomes from a prospective study of drug-induced liver injury in the United States[J].Gastroenterology,2008,135(6):1924-1934.

[82]BORRAZ Y,FERNANDEZ MC,GARCIA-MUHOZ B,et al.Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury(DILI)?[C].61st Annual Meeting of the American Association for the Study of Liver Diseases,2010:a270.

[83]ROBLES-DIAZ M,LUCENA MI,KAPLOWITZ N,et al.Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J].Gastroenterology,2014,147(1):109-118.

[84]LEISE MD,POTERUCHA JJ,TALWALKAR JA.Drug-induced liver injury[J].Mayo Clin Proc,2014,89(1):95-106.

[85]GAO H,LI N,WANG JY,et al.Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids[J].J Dig Dis,2012,13(1):33-39.

[86]FAN CQ,CRAWFORD JM.Sinusoidal obstruction syndrome(hepatic veno-occlusive disease)[J].J Clin Exp Hepatol,2014,4(4):332-346.

[87]KOOTTE AM,SIEGEL AM,KOORENHOF M.Generalised peliosis hepatis mimicking metastases after long-term use of oral contraceptives[J].Neth J Med,2015,73(1):41-43.

[88]YU CY,CHANG LC,CHEN LW,et al.Peliosis hepatis complicated by portal hypertension following renal transplantation[J].World J Gastroenterol,2014,20(9):2420-2425.

[89]GREEN RM,FLAMM S.AGA technical review on the evaluation of liver chemistry tests[J].Gastroenterology,2002,123(4):1367-1384.

[90]WATKINS PB,DESAI M,BERKOWITZ SD,et al.Evaluation of drug-induced serious hepatotoxicity(e DISH):application of this data organization approach to phaseⅢclinical trials of rivaroxaban after total hip or knee replacement surgery[J].Drug Saf,2011,34(3):243-252.

[91]EGUCHI A,WREE A,FELDSTEIN AE.Biomarkers of liver cell death[J].J Hepatol,2014,60(5):1063-1074.

[92]WATKINS PB,SELIGMAN PJ,PEARS JS,et al.Using controlled clinical trials to learn more about acute drug-induced liver injury[J].Hepatology,2008,48(5):1680-1689.

[93]FANNIN RD,RUSSO M,O'CONNELL TM,et al.Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation[J].Hepatology,2010,51(1):227-236.

[94]SU YW,CHEN X,JIANG ZZ,et al.A panel of serum microRNAs as specific biomarkers for diagnosis of compound-and herb-induced liver injury in rats[J].PLo S One,2012,7(5):e37395.

[95]BALA S,PETRASEK J,MUNDKUR S,et al.Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic,drug-induced,and inflammatory liver diseases[J].Hepatology,2012,56(5):1946-1957.

[96]ANTOINE DJ,DEAR JW,LEWIS PS,et al.Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital[J].Hepatology,2013,58(2):777-787.

[97]WATKINS PB.Biomarkers for drug-induced liver injury[M]//KAPLOWITZ N,DELEVE LD.Drug-Induced Liver Disease.3rd ed.San Diego:Academic Press,2013:275-286.

[98]KENNA JG.Current concepts in drug-induced bile Salt Export Pump(BSEP)Interference[J].Curr Protoc Toxicol,2014,61:23.7.1-23.7.15.

[99]LIN G,WANG JY,LI N,et al.Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J].J Hepatol,2011,54(4):666-673.

[100]STEPHENS C,ANDRADE RJ,LUCENA MI.Mechanisms of drug-induced liver injury[J].Curr Opin Allergy Clin Immunol,2014,4(4):286-292.

[101]VUPPALANCHI R,IANGPUNSAKUL S,CHALSANI N.Etiology of new-onset jaundice:how often is it caused by idiosyncratic drug-induced liver injury in the United States[J].Am J Gastroenterol,2007,102(3):558-562.

[102]LORAS C,GISBER JP,MINGUEZ M,et al.Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy[J].Gut,2010,59(10):1340-1346.

[103]MAKAR GA,WEINER MG,KIMMEL SE,et al.Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population[J].Pharmacoepidemiol Drug Saf,2008,17(1):43-51.

[104]AITHAL GP,WATKINS PB,ANDRADE RJ,et al.Case definition and phenotype standardization in drug-induced liver injury[J].Clin Pharmacol Ther,2011,89(6):806-815.

[105]DANAN G,BENICHOU C.Causality assessment of adverse reactions to drugs I.A novel method based on the conclusions of international consensus meetings:application to drug induced liver injuries[J].J Clin Epidemiol,1993,46(11):1323-1330.

[106]MARIA VAJ,VICTORINO RMM.Development and validation of a clinical scale for the diagnosis of drug induced hepatitis[J].Hepatology,1997,26(3):664-669.

[107]HAYASHI PH.Causality assessment in drug-induced liver injury[J].Semin Liver Dis,2009,29(4):348-356.

[108]Roussel Uclaf Causality Assessment Method(RUCAM)in drug induced liver injury[DB/OL].http://www.livertox.nih.gov/rucam.html.

[109]LUCENA MI,CAMARGO R,ANDRADE RJ,et al.Comparison of two clinical scales for causality assessment in hepatotoxicity[J].Hepatology,2001,33(1):123-130.

[110]GARCA-CORTSM,LUCENA MI,PACHKORIA K,et al.Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury[J].Aliment Pharmacol Ther,2008,27(9):780-789.

[111]滝川一,恩地森一,高森賴雪.DDW-J2004ヮ—クショツプ药物性肝障害诊断基准の提案[J].肝臓,2005,46(2):85-90.

[112]Cooperative Group for Hepatic and Gall Diseases,Chinese Society of Gastroenterology,Chinese Medical Association.Recommendations on the diagnosis and treatment of acute drug-induced liver injury(Draft)[J].Chin J Dig,2007,27(11):765-767.(in Chinese)中华医学会消化病学分会肝胆疾病协作组.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767.

[113]ROCKEY DC,SEEFF LB,ROCHON J,et al.Causality assessment in drug-induced liver injury using a structured expert opinion process:comparison to the roussel-uclaf causality assessment method[J].Hepatology,2010,51(6):2117-2126.

[114]Severity grading in drug induced liver injury[DB/OL].http://livertox.nih.gov/Severity.html.

[115]Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association,Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Diagnostic and treatment guidelines for liver failure(2012 version)[J].Chin J Hepatol,2013,21(3):178-179.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华肝脏病杂志,2013,21(3):178-179.

[116]PALMORE TN,SHAH NL,LOOMBA R,et al.Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression[J].Clin Gastroenterol Hepatol,2009,7(10):1130-1137.

[117]SUZUKI A,BRUNT EM,KLEINER DE,et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology,2011,54(3):931-939.

[118]MIAO Q,BIAN Z,TANG R,et al.Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J].Clin Rev Allergy Immunol,2015,48(2-3):226-235.

[119]BJORNSSON E,TALWALKAR J,TREEPRASERTSUK S,et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis[J].Hepatology,2010,51(6):2040-2048.

[120]NAVARRO VJ,SENIOR JR.Drug-related hepatotoxicity[J].N Engl J Med,2006,354(7):731-739.

[121]WU S,XIA Y,LV X,et al.Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients[J].J Gastroenterol Hepatol,2015,30(3):540-545.

[122]FORD R,SCHWARTZ L,DANCEY J,et al.US Food and Drug Administration.Center for Drug Evaluation and Research(CDER),Center for Biologics Evaluation and Research(CBER).Guidance for industry:drug-induced liver injury—premarketing clinical evaluation[J].Eur J Cancer,2009,45(2):268-274.

[123]MAO YM,LIU XL,CHEN CW.Introduction of 2013 FDA Guidelines for drug-induced liver injury[J].Chin Hepatol,2013,18(5):325-330.(in Chinese)茅益民,刘晓琳,陈成伟.2013年美国FDA药物性肝损伤指南介绍[J].肝脏,2013,18(5):325-330.

[124]HEARD KJ.Acetylcysteine for acetaminophen poisoning[J].N Engl J Med,2008,359(3):285-292.

[125]MASUBUCHI Y,NAKAYAMA J,SADAKATA Y.Protective effects of exogenous glutathione and related thiol compounds against drug-induced liver injury[J].Biol Pharm Bull,2011,34(3):366-370.

[126]BERK M,MALHI GS,GRAY LJ,et al.The promise of N-acetylcysteine in neuropsychiatry[J].Trends Pharmacol Sci,2013,34(3):167-177.

[127]ZWINGMANN C,BILODEAU M.Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver[J].Hepatology,2006,43(3):454-463.

[128]REUBEN A,KOCH DG,LEE WM.Drug-induced acute liver failure:results of a U.S.multicenter,prospective study[J].Hepatology,2010,52(6):2065-2076.

[129]LEE WM,HYNAN LS,ROSSARO L,et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure[J].Gastroenterology,2009,137(3):856-864.

[130]BATEMAN DN,DEAR JW,THANACOODY HK,et al.Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning:a randomised controlled trial[J].Lancet,2014,383(9918):697-704.

[131]SINGH S,HYNAN LS,LEE WM,Acute Liver Failure Study Group.Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure[J].Dig Dis Sci,2013,58(5):1397-1402.

[132]LEE WM,STRAVITZ RT,LARSON AM.Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011[J].Hepatology,2012,55(3):965-967.

[133]MAO YM,ZENG MD,CHEN Y,et al.Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases:a randomized,double-blind,multi-doses,active drug controlled,muitl-center study[J].Chin J Hepatol,2009,17(11):847-851.(in Chinese)茅益民,曾民德,陈勇,等.异甘草酸镁治疗ALT升高的慢性肝病的多中心、随机、双盲、多剂量、阳性药物平行对照研究[J].中华肝脏病杂志,2009,17(11):847-851.

[134]LI X,ZHOU J,CHEN S,et al.Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60years of age with cancer[J].J Int Med Res,2014,42(4):906-914.

[135]CHU NH,LI L,ZHANG X,et al.Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease[J].Int J Tuberc Lung Dis,2015,19(4):475-480.

[136]ZHANG QH,SHI GF,LI Q.Diammonium glycyrrhizinate enteric-coated capsules in treatment of chronic hepatitis[J].Chin J Infect Dis,2007,25(3):175-176.(in Chinese)张琼华,施光峰,李谦.甘草酸二胺肠溶胶囊治疗慢性肝炎2396例[J].中华传染病杂志,2007,25(3):175-176.

[137]Ministry of Health,Labour and Welfare,Japan.Clinical guidelines for severe side effects-drug-induced liver injury[S].2008.(in Chinese)日本厚生劳动省.重症副作用临床指导手册——药物性肝损害[S].2008.

[138]ABENAVOLI L,CAPASSO R,MILIC N,et al.Milk thistle in liver diseases:past,present,future[J].Phytother Res,2010,24(10):1423-1432.

[139]NATHWANI RA,KAPLOWITZ N.Drug hepatotoxicity[J].Clin Liver Dis,2006,10(2):207-217.

[140]NI LD,XIE Q,LI HW,et al.Ursodeoxycholic acid in the treatment of drug-induced liver injury:an open controlled clinical trial[J].Chin Hepatol,2009,14(4):278-280.(in Chinese)倪鎏达,谢青,李捍卫,等.熊去氧胆酸治疗药物性肝损伤开放对照临床试验[J].肝脏,2009,14(4):278-280.

[141]ZHAO P,DUAN GF,DU L,et al.Systematic evaluation on the emcacy of ademetionine in patients with drug-induced lier injury[J].Chin J Gastroenterol Hepatol,2011,20(4):341-344.(in Chinese)赵攀,段光锋,杜丽,等.腺苷蛋氨酸治疗药物性肝损伤效果的系统评价[J].胃肠病学和肝病学杂志,2011,20(4):341-344.

[142]MATO JM,LU SC.Role of S-adenosyl-L-methionine in liver health and injury[J].Hepatology,2007,45(5):1306-1312.

[143]VINCENZI B,SANTINI D,FREZZA AM,et al.The role of Sadenosyl methionine in preventing FOLFOX-induced liver toxicity:a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen[J].Expert Opin Drug Saf,2011,10(3):345-349.

[144]JEONG R,LEE YS,SOHN C,et al.Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury[J].Scand J Gastroenterol,2015,50(4):439-446.

[145]YU YC,CHEN CW.Interpretation of ACG guidelines for the clinical diagnosis and treatment of idiosyncratic drug-induced liver injury[J].Chin Hepatol,2014,19(8):570-574.(in Chinese)于乐成,陈成伟.ACG特异质性药物性肝损伤临床诊治指南解读[J].肝脏,2014,19(8):570-574.

[146]ZHANG L,YANG XH.Pharmacovigilance idea should be introduced sufficiently into the safety monitoring and evaluation process of chinese drugs[J].Chin J Integr Tradit West Med,2009,29(9):863-866.(in Chinese)张力,杨晓晖.在中药安全性监测和评价过程中充分引入药物警戒理念[J].中国中西医结合杂志,2009,29(9):863-866.

[147]ZHANG L,WONG LY,HE Y,et al.Pharmacovigilance in China:current situation,successes and challenges[J].Drug Saf,2014,37(10):765-770.

[148]GRAHAM DJ,MOSHOLDER AD,GELPERIN K,et al.Pharmacoepidemiology and risk management[M]//STROM BL.Pharmacoepidemiology.4th ed.West Sussex,England:John Wiley&Sons,Ltd.,2005:51530.

[149]WATKINS PB,BLOOM J,HUNT C.Biomarkers of acute idiosyncratichepatocellular injury in clinical trials[M]//OLSON S,ROBINSON S,GIFFIN R.Accelerating the development of biomarkers for drug safety:workshop summary.Washington:National Academies Press,2009:4257.

[150]WILLY M,LI Z.What is prescription labeling communicating to doctors about hepatotoxic drugs?A study of FDA-approved product labeling[J].Pharmacoepidemiol Drug Saf,2004,13(4):201-206.